Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.61 |
| ▸ | MMP2 | P08253 | 5/20 | 0.56 |
| ▸ | MMP9 | P14780 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 7/20 | 0.50 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569109 | 0.85 | APP (0.63) | APPMMP2MMP9KDM4ESMN1; SMN2 | |
| SCHEMBL5727440 | 0.84 | HDAC6 (0.56) | MMP2MMP9IKBKBCNR1HSD17B1 | |
| SCHEMBL959465 | 0.83 | APP (0.61) | APPMMP2MMP9KDM4ESMN1; SMN2 | |
| SCHEMBL7060203 | 0.83 | MMP2 (0.47) | APPMMP2MMP9MMP13MMP3 | |
| SCHEMBL3255085 | 0.83 | MMP13 (0.49) | MMP2MMP9MAPTMMP13MMP3 | |
| SCHEMBL3111282 | 0.80 | MMP2 (0.56) | APPMMP2MMP9KDM4ESMN1; SMN2 | |
| SCHEMBL7057708 | 0.80 | MMP2 (0.41) | MMP2MMP9SMN1; SMN2NPC1MMP13 | |
| SCHEMBL11519257 | 0.78 | APP (0.54) | APPMMP2MMP9ALDH1A1GAA | |
| SCHEMBL1181273 | 0.78 | APP (1.00) | APPKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5727054 | 0.77 | RAB9A (0.46) | APPMMP2MMP9KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122538-B2 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-10-17 | — | — | US | claimed |
| EP-1549639-B1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LTD (GB) | 2006-05-24 | — | — | EP | claimed |
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | claimed |
| EP-1549639-A1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | claimed |
| WO-2004031181-A1 | SULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-04-15 | — | — | WO | claimed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | APP 290/4885MMP2 16/4885MMP9 8/4885 |
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | SIGMAR1, CHRM1, NPSR1 | APP 3590/4885MMP2 4785/4885MMP9 4681/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | APP 290/4885MMP2 16/4885MMP9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.